Nucynta ER/Palexia SR (Neuropathic Pain) - Forecast and Market Analysis to 2022
Summary
Neuropathic pain (NP) is defined as a disorder of the sensorimotor system and is distinctly different from nociceptive pain, which is a consequence of trauma, injury, or inflammation. The main difference between neuropathic and nociceptive pain is the absence of a continuous nociceptive input in neuropathic pain. Although the term neuropathic pain is used to describe a wide range of pain syndromes with varying etiologies, this report focuses on 3 distinct forms of NP: Painful diabetic neuropathy, Postherpetic neuralgia and trigeminal neuralgia. The main classes of drugs used to treat these three neuropathic pain indications include anticonvulsants, antidepressants, opioids and topical treatments. However, despite the availability of multiple pain medications only 50% of patients respond to any given drug and there are numerous the side effects associated particularly with systemically administered drugs, that reduce their tolerability.
Visit Complete Report Here: http://www.marketresearchreports.biz/analysis-details/nucynta-erpalexia-sr-neuropathic-pain-forecast-and-market-analysis-to-2022
New treatments will target some key unmet needs in terms of efficacy and tolerability, but opportunities will remain for drugs that can more reliably eradicated NP in targeted patient populations, as well as offering an improved safety profile.
Nucynta ER/Palexia SR (tapentadol) is an opioid analgesic that was developed by Grnenthal in conjunction with Johnson & Johnson (J&J), first as an immediate-release formulation indicated for acute pain, and later as an ER formulation for the management of chronic pain. Tapentadol has a dual mechanism of action as an agonist of the -opioid receptor and as a norepinephrine reuptake inhibitor, and was developed as an improvement to tramadol, which has weak opioid activity, but also inhibits the reuptake of both serotonin and...